1. | Circular Memo for ensuring the use of authentic Indian Pharmacopoeia, IP Reference Standards IPRS and impurity standards for quality testing of drugs. |
2. | Circular issued regarding certain instructions on sale of Oxytocin |
5. | Public Notice dated 03 September 2024 - Sale of Formulations containing Pregabalin - Restrictions - Reg. |
6. | Circular regarding sourcing of Plasma or any other biological matrices by CROs, BA-BE Centres from Blood Centres for bioanalytical purposes. |
8. | Circular regarding issuance of NOCs for Specific Quantity Export of New Drugs and Banned Drugs by CDSCO Zonal Office w.e.f. 15th May 2024 |
9. | Public Notice - Spurious Drug Alert and Stop-Use Notice - Spurious Drugs Claimed to be Manufactured by Meg Lifesciences, a Fictitious Firm. |
10. | Public Advisory issued by DCA Telangana on Prices of Essential Medicines |
11. | Public Advisory issued by DCA Telangana on Spurious Drugs |
12. | Public Advisory issued by DCA Telangana on Antimicrobial Resistance AMR |
13. | Circular regarding sale of Hydrogen Peroxide Solution by retail medical shops. |
14. | Gazette Notification Drug formulation products specified in Schedule H2 (300 formulation brand names) which shall bear Bar Code or Quick Response Code to facilitate authentication |
15. | DCA - Circular on Risk-based Sampling |
16. | DCA - Advisory Procurement and testing of the raw materials Glycerin and Propylene Glycol by the Cough Syrup manufacturers |
17. | Classification of Medical Devices - List of Medical Devices, IVDs along with their risk class under provisions of sub-rule 1 Rule 4 of the Medical Devices Rules, 2017 |
18. | Medical Devices Rules 2017 |
19. | List of Notified Bodies registered with CDSCO under Medical Devices Rules. |
20. | Grouping guidelines for Medical Devices applications |
21. | FAQs on Medical Devices Rules |
22. | Notice regarding List of Reference Products for conduct of BE Study for Oral Solid Dosage Forms containing BCS Class II and Class IV drugs |
23. | Prohibition of certain FDCs appeared in the list of 294 FDCs, under Section 26A |
24. | Fixed Dose Combinations FDCs approved by DCG (I) since 1961 to 31st December 2019 |
25. | GUIDELINES FOR TAKING ACTION ON SAMPLES OF DRUGS DECLARED SPURIOUS OR NOT OF STANDARD QUALITY |
26. | Standards for Blood Banks and Blood Transfusion Services |
27. | Guideline issued by CDSCO for uploading manufacturing sites and formulation data on the SUGAM Portal by manufacturers |
28. | Blood Centres - Charges - Blood and Blood Components as per Guidelines for Processing Charges issued by the Government of India. |
29. | Procedure for submission of cough syrups to be exported by manufacturer, exporter directly to Central, NABL accredited state testing laboratories for testing purpose. |
30. | Instructions issued to Drugs Inspectors regarding regulation of sale and distribution of N95 Masks, PPE, Hand Sanitizers and related medicines. |
31. | Guidance Document and Steps to be followed by the manufcaturers/importers for registration of Non-notified Medical Devices. |
32. | Cosmetics Rules 2020 |
33. | Circular regarding procedure to be adopted in the investigation and recall of the drugs declared as NSQ or Spurious |
34. | Circular issued regarding strict enforcement of testing of Aluminum in Purified Water, raw materials used for preparation of Dialysis Solutions and in the final product Haemodialysis Solutions. |
35. | Implementation of regulation of pre shipment document verification, physical inspection, QC testing, issuance of CRIA for pharmaceuticals to be exported to The Gambia by Medicines Control Agency |
36. | Circular regarding Rule 84AB for uploading data of drug manufacturing facilities and approved drug formulations on SUGAM portal |
37. | Circular of DCGI regarding modalities of Joint Inspection for Grant of Manufacturing Licence |
38. | GSR 1337E dated 27-10-2017 regarding retention of licences, omission of renewal |
39. | Consequential Amendments to GSR 1337E Gazette Notification |
40. | New Drugs and Clinical Trial Rules 2019 |
41. | FAQs on New Drugs and Clinical Trial Rules 2019 |
Designed, Developed and Hosted by National Informatics Centre, Hyderabad.
Content owned, maintained and updated by Department of Drugs Control Administration, Government of Telangana